Bayer Healthcare gives $5m to biopharmaceutical company Trius

As reported by the Pharmaceutical Business Review, biopharmaceutical company, Trius Therapeutics has received $5m payment from Bayer Healthcare.

The payment came after a successful late-stage trial of an experimental skin infection treatment called Tedizolid. It was found that the drug was as effective in treating infections such as MRSA which are slowly become resistant to antibiotics.

Trius will begin their second late-stage trial in September with results expected in early 2013. These results will be used to help their applications for drug approval with the Food and Drug Administration and the European Medicines Agency.

Click here to search our pharmaceutical jobs now.

Posted in: Featured Jobs, News
CK Logo in place of featured image